Curis (FRA:CUS1) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CUS1 Curis Inc FRA:CUS1
55 GF Score
Price €3.93
GF Value €1.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Curis Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:CUS1
55GF Score
Curis Inc FRA:CUS1
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Curis (FRA:CUS1) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be overvalued. The current stock price of €3.93 is trading 204.7% above its estimated GF Value™ of €1.29. GuruFocus considers Curis to be Significantly Overvalued.

Key valuation signals for FRA:CUS1:

  • Dividends Received:
  • GF Value™: €1.29 vs. price of €3.93 (204.7% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:CUS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Curis Business Description

Other Exchanges CRIS:USA
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
55GF Score

Get the complete analysis for FRA:CUS1

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.93
Price
€1.29
GF Value